Chiqing Ying

Ms. Chiqing Ying


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CYChiqing Ying
Chiqing Ying
XLXukun Li
Xukun Li
SLShuangzhi Lv
Shuangzhi Lv
PDPeng Du
Peng Du
YCYunzhi Chen
Yunzhi Chen
WWWei Wu
Wei Wu
This study aimed to establish a diagnostic algorithm combining T-SPOT with computed tomography image analysis based on deep learning (DL) for early differential diagnosis of nontuberculous mycobacteria pulmonary disease (NTM-PD) and pulmonary tuberculosis (PTB). A total of 1049 cases were enrolled, including 467 NTM-PD and 582 PTB cases. A total of 320 cases (160 NTM-PD and 160 PTB) were randomized as the testing set and were analyzed using T-SPOT combined with the DL model. The testing cases were first divided into T-SPOT-positive and -negative groups, and the DL model was then used to separate the cases into four subgroups further. The precision was found to be 91.7% for the subgroup of T-SPOT-negative and DL classified as NTM-PD, and 89.8% for T-SPOT-positive and DL classified as PTB, which covered 66.9% of the total cases, compared with the accuracy rate of 80.3% of T-SPOT alone. In the other two remaining groups, where the T-SPOT prediction was inconsistent with the DL model, the accuracy was 73.0% and 52.2%, separately. Our study shows that the new diagnostic system combining T-SPOT with DL based computed tomography image analysis can greatly improve the classification precision of NTM-PD and PTB when the two methods of prediction are consistent.

1 December 2022 in Journal of Zhejiang University (Medical Sciences)
Verified
Journal Article
Closed access
CYChiqing Ying
Chiqing Ying
CHChang He
Chang He
KXKaijin Xu
Kaijin Xu
YLYongtao Li
Yongtao Li
YZYing Zhang
Ying Zhang
WWWei Wu
Wei Wu
全球约有四分之一人口曾感染结核分枝杆菌,5%~10%结核潜伏感染者会向活动性结核患者转化,正确诊治结核潜伏感染是终止结核病流行的重要内容之一。目前,结核潜伏感染的诊断方法如结核菌素皮肤试验、γ干扰素释放试验等存在无法区分结核潜伏感染和活动性结核的局限性,通过检测一些特征性生物标志物(如外周血转录组基因)将有助于区分两者。人类免疫缺陷病毒感染者、使用免疫制剂者、器官移植患者以及密切接触活动性结核患者等高危人群有必要进行结核潜伏感染监测。对于结核潜伏感染人群,应根据进展为活动性结核的风险大小及获益程度来决定是否治疗。预防性结核潜伏感染治疗方案包括异烟肼单药治疗6或9个月、利福平单药治疗4个月、每周一次服用利福喷丁+异烟肼3个月(3HP方案)、每日一次服用利福平+异烟肼3个月(3RH方案)。每日一次利福喷丁+异烟肼1个月方案(1HP方案)的成功提示超短疗程具有可行性,但其疗效仍需进一步评估。与耐多药结核病患者密切接触的结核潜伏感染人群如何进行预防性治疗仍在探索中,包括使用抗结核新药,如贝达喹啉、德拉马尼及氟喹诺酮等药物及组合方案。本文结合近年来国内外防治指南及相关研究进展,总结了当前结核潜伏感染的诊治现状及未来发展方向。

16 October 2024 in Thorax
Verified
Journal Article
Open access
PDF file
CYChiqing Ying
Chiqing Ying
LZLvjun Zhang
Lvjun Zhang
XJXuehang Jin
Xuehang Jin
HCHui Chen
Hui Chen
DZDan Zhu
Dan Zhu
The results of metagenomic next-generation sequencing.